Sort
48,018 grants matching “immunotherapy”
Mechanisms of vaccine protection against AIDS-associated Cryptococcus infection
$749,562Amariliz Rivera · Rbhs-New Jersey Medical School · R01 · FY2019 · AI
Targeting virus-specific CAR T cells to lymphoid follicles to achieve durable HIV suppression
$749,449Pamela J Skinner · University Of Minnesota · R01 · FY2019 · AI
Immune determinants of progression from Oral Epithelial Dysplasia to Oral Squamous Cell Carcinoma by precision multiplexed imaging
$749,410Matthew Spitzer · University Of California, San Francisco · R01 · FY2022 · DE
B-CLL Biology: Impact of Combination Therapy
$749,408Mayo Clinic · R01 · FY2004 · CA
Project 1 - Clinical Trial
$749,398Andrew R Haas · University Of Pennsylvania · P01 · FY2020 · CA
Project 1 - Clinical Trial
$749,398Andrew R Haas · University Of Pennsylvania · P01 · FY2021 · CA
Project 1 - Clinical Trial
$749,397Andrew R Haas · University Of Pennsylvania · P01 · FY2018 · CA
Uncovering the Biology of Resistance to Tyrosine Kinase Inhibitors in EGFR Mutant Lung Cancer Patient-Derived Models.
$749,308Katerina Abigail Politi · Yale University · U01 · FY2022 · CA
OVERCOMING IMMUNE ESCAPE MECHANISMS IN IMMUNOTHERAPY OF NEUROBLASTOMA
$749,250Children'S Hospital Los Angeles · · FY2017 · Department of the Army
Clinical Evaluation of Chlorotoxin-redirected Chimeric Antigen Receptor (CAR) T cells for Treatment of Glioblastoma
$749,221Christine Brown · Beckman Research Institute/City Of Hope · R01 · FY2021 · CA
Decoding and reprogramming T cells through synthetic biology for cancer immunotherapy
$749,187Alexander Marson · J. David Gladstone Institutes · R01 · FY2025 · CA
Identification of human tumor-associated antigens
$749,175Kwong Yok Tsang · Division Of Basic Sciences - Nci · ZIA · FY2011 · CA
A Platform Technology to Genetically Reprogram Cancer Cells for Enhanced Immunotherapy
$749,156Stephany Yi Tzeng · Johns Hopkins University · R37 · FY2025 · CA
Chemical Optimization of a novel class of USP7 inhibitor for cancer treatment
$748,944Joseph Weinstock · Progenra, Inc. · R44 · FY2016 · CA
Chemical Optimization of a novel class of USP7 inhibitor for cancer treatment
$748,944Joseph Weinstock · Progenra, Inc. · R44 · FY2017 · CA
Stratifying Patient Immune Endotypes in Sepsis (SPIES Study)
$748,859Lyle L Moldawer · University Of Florida · R01 · FY2022 · GM
Project 1 - Evolutionary and ecological dynamics of tumor-host interactions
$748,658Robert J Gillies · H. Lee Moffitt Cancer Ctr & Res Inst · U54 · FY2018 · CA
Monoclonal Antibody Therapeutics for Candida auris
$748,593Arturo Casadevall · Johns Hopkins University · U19 · FY2025 · AI
Developing broad-spectrum therapeutics against C. difficile toxins
$748,253Rongsheng Jin · University Of California-Irvine · R01 · FY2025 · AI
Dissecting the Source and Mechanisms of IL-17-Mediated Modulation of Pancreatic Tumorigenesis
$748,012Florencia McAllister · University Of Tx Md Anderson Can Ctr · R37 · FY2025 · CA
NIH Myeloid Malignancy Program
$747,993Steven Pavletic · Division Of Basic Sciences - Nci · ZIA · FY2024 · CA
Activation of Human Natural Killer Cell Function
$747,792Eric O Long · National Institute Of Allergy And Infectious Diseases · ZIA · FY2011 · AI
Comprehensive antigenic mapping of the human anti-peanut IgE antibody response
$747,580Scott Alan Smith · Vanderbilt University Medical Center · R01 · FY2025 · AI
Natural killer cell engineering to target the HIV reservoir
$747,575Jerome A. Zack · University Of California Los Angeles · R01 · FY2024 · AI
Mechanisms of Chronic Hepatitis B Infection and Therapeutic Vaccines
$747,395David R. Milich · Vaccine Research Institute Of San Diego · R01 · FY2008 · AI